Agenus Announces Positive Preliminary Results of iNKT Cell Therapy Trial in COVID-19
3 out of 4 intubated patients were discharged after treatment 2 out of 4 patients were extubated within 24 hours of dosing LEXINGTON, Mass., Feb. 04, 2021 (GLOBE NEWSWIRE) -- Agenus Inc. (NASDAQ: AGEN), an immuno-oncology company with an extensive pipeline …